Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 9, 2025 • 10:01 AM ET

Date/Time Source News Release
06/03/2025 07:00 AM EDT Business Wire Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis
05/21/2025 07:00 AM EDT Business Wire Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences
05/12/2025 07:00 AM EDT Business Wire Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome
05/08/2025 07:00 AM EDT Business Wire Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results
05/07/2025 08:00 AM EDT Business Wire Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences
05/01/2025 09:00 AM EDT Business Wire Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
04/30/2025 07:00 AM EDT Business Wire Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia
04/16/2025 02:00 PM EDT GlobeNewswire Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
04/09/2025 07:00 AM EDT Business Wire Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis
04/02/2025 09:00 AM EDT Business Wire Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Page

Additional News

As of June 9, 2025 • 10:01 AM ET

Date/Time Source News Release
06/08/2025 10:00 AM EDT ACCESS Newswire IA Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation
06/05/2025 10:00 AM EDT ACCESS Newswire IA Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
06/03/2025 10:00 AM EDT ACCESS Newswire IA Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation
06/03/2025 09:02 AM EDT SeekingAlpha Amylyx gets FDA fast track status for ALS treatment
06/01/2025 10:00 AM EDT ACCESS Newswire IA Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect
05/29/2025 10:05 AM EDT ACCESS Newswire IA Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect
05/27/2025 10:00 AM EDT ACCESS Newswire IA Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation
05/25/2025 10:00 AM EDT ACCESS Newswire IA Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation
05/22/2025 10:00 AM EDT ACCESS Newswire IA Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
05/20/2025 10:00 AM EDT ACCESS Newswire IA Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.